Champions Oncology vs Invivyd
Champions Oncology reported revenue of $59 million in fiscal 2026, about the same as Invivyd's $53 million in fiscal 2025. Champions Oncology's revenue grew 4.4% in its latest year, and Invivyd's grew 110.5%. Champions Oncology had an operating margin of -1.9%, against -104.0% at Invivyd. Free cash flow was −$5 million at Champions Oncology and −$58 million at Invivyd. Their fiscal years end in different months (April 30 and December 31), so the periods don't line up exactly.
Side by side
| Champions Oncology | Invivyd | |
|---|---|---|
| Latest fiscal year | FY2026, Apr 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $59M | $53M |
| Revenue growth | 4.4% | 110.5% |
| Revenue growth a year, last 5 years | 7.7% | — |
| Gross margin | 48.0% | — |
| Operating margin | −1.9% | −104.0% |
| Net margin | −2.0% | −98.2% |
| Free cash flow | −$5M | −$58M |
| Free cash flow margin | −8.5% | −109.1% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −3.0% | 45.3% |
| Last close | $4.40 | $0.45 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $341,120 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Champions OncologyInvivyd
Operating margin
Percent of revenue
Champions OncologyInvivyd
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Champions OncologyInvivyd
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Champions Oncology and Invivyd pages.